You are here: Home » Companies » News
Business Standard

Aurobindo Pharma gets USFDA nod for pain reliever Ibuprofen; launch in Sept

Quoting Nielsen data, Aurobindo Pharma said the estimated market size of ibuprofen capsules OTC is $164 million for the twelve months ending March 2018

Press Trust of India  |  New Delhi 

Aurobindo Pharma

has received final approval from the US health regulator to manufacture and market capsules, used to relieve pain and reduce fever.

The approved product is a generic equivalent of Pfizer's Advil Liqui-Gels Capsules. The product will be launched in September 2018.

"The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture capsules OTC, 200 mg," said in a BSE filing.

Quoting Nielsen data, said the estimated market size of capsules OTC is $164 million for the twelve months ending March 2018.

The pharma company said it has now a total of 373 ANDA (Abbreviated New Drug Application) approvals (340 final approvals, including 17 from Aurolife Pharma LLC and 33 tentative approvals) from the USFDA.

Stock of Aurobindo Pharma was trading 0.61 per cent higher at Rs 610.25 on BSE.

First Published: Mon, July 02 2018. 11:38 IST
RECOMMENDED FOR YOU